Cationic-Anionic Nanoparticle Kits for Stable, Rapid Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nanoparticle-based drug delivery systems face challenges with stability during storage and transportation, requiring complex production processes and are not easily adaptable to different drugs, which hinders efficient and rapid delivery, especially in personalized medicine and pandemic situations.
Innovation Solution
A kit comprising separate chambers with cationic and anionic compounds, including an anionic polymer with acid functional groups, allows for simple mixing to form drug-containing nanoparticles, ensuring stability and efficient delivery regardless of environmental conditions, with specific targeting to the spleen for enhanced anticancer vaccine usability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nanoparticles are prepared using conventional methods with cationic lipids or polymers, then intracellular delivery is improved, but stability during storage and transportation deteriorates
Solution Approach 1:
The patent uses a composite nanoparticle system comprising cationic lipids or polymers combined with anionic polymers. This composite structure allows the cationic component to provide intracellular delivery efficiency through electrostatic interaction with nucleic acids, while the anionic polymer component enhances stability during storage and transportation by forming a stable complex structure that protects the drug payload
Solution Approach 2:
The patent optimizes specific parameters including the molecular weight of polymers (5,000-500,000 for cationic polymers, 1,000-100,000 for anionic polymers), the N/P ratio (0.5-5), and nanoparticle size (50-500 nm). These parameter changes enable the nanoparticle to maintain both high intracellular delivery efficiency and stability during storage and transportation
2Stability of the object's composition
If complex production processes are used to secure sufficient stability, then stability is improved, but ease of manufacture deteriorates
Solution Approach 1:
The patent employs preliminary action by pre-formulating standardized nanoparticle compositions with optimized ratios of cationic and anionic components. The nanoparticle preparation kit includes pre-measured components that can be simply mixed together, eliminating the need for complex step-by-step manufacturing processes while maintaining high stability. The anionic polymer is pre-synthesized with specific functional groups that ensure stable complex formation
Solution Approach 2:
The patent creates a universal nanoparticle platform that can deliver various types of drugs (nucleic acids, proteins, peptides) using the same basic formulation approach. The standardized kit design with universal components allows the same manufacturing simplicity to be applied across different drug types while maintaining stability
3Productivity
If ready-made nanoparticles are developed, then productivity is improved, but adaptability to different drugs deteriorates
Solution Approach 1:
The patent designs a universal nanoparticle platform with multi-functional capabilities. The cationic component can complex with various anionic drugs (nucleic acids, proteins, peptides) through electrostatic interaction, while the anionic polymer provides stable encapsulation. This universal design allows the same ready-made nanoparticle formulation to be adapted to different drug types without requiring complex re-engineering, thus maintaining both high productivity and adaptability
Solution Approach 2:
The patent segments the nanoparticle into distinct functional components (cationic lipid/polymer for delivery, anionic polymer for stability and encapsulation). This segmentation allows each component to be optimized independently while maintaining overall system performance, enabling the ready-made nanoparticle to be easily adapted to different drugs by simply changing the drug payload while keeping the delivery system constant
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit enables rapid preparation of stable drug-containing nanoparticles suitable for various drugs, enhancing cell delivery efficiency and allowing prompt administration without complex processes, particularly for personalized vaccines and pandemic responses.
Implementation Method 1
a complex of cationic lipid and nucleic acid (lipoplex) and a complex of polycationic polymer and nucleic acid (polyplex). Such a cationic lipid or polycationic polymer stabilizes anionic drug by forming a complex through electrostatic interaction with the anionic drug and increases intracellular delivery
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a kit for construction of drug-containing nanoparticles and a nanoparticle composition for drug delivery. More specifically, the present invention concerns a kit for construction of drug-containing nanoparticles and a nanoparticle composition for drug delivery, each designed to increase the efficiency of cellular drug delivery by utilizing nanoparticles that include a cationic compound and an anionic polymer compound with at least one acidic functional group.